KCNJ2 Biomarker Diagnosis for EoE and PPI-REE Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for eosinophilic esophagitis (EoE) and proton pump inhibitor responsive esophageal eosinophilia (PPI-REE) are indistinguishable, leading to unclear therapeutic strategies and the need for a proton pump inhibitor (PPI) trial to differentiate between the two conditions, which is ineffective for EoE.

Innovation Solution

The use of the KCNJ2/Kir2.1 gene or gene product as a biomarker to differentiate EoE from PPI-REE by determining its expression level in an esophageal biopsy sample, allowing for accurate diagnosis without a PPI trial, using methods such as quantitative PCR or immunofluorescence-based techniques.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a PPI trial is used to differentiate EoE from PPI-REE, then the diagnosis can be made based on treatment response, but the diagnostic process becomes time-consuming and delays effective treatment

Engineering Contradiction:

Improvediagnostic accuracyVSAvoiddiagnostic time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by measuring KCNJ2 gene or protein expression levels in esophageal biopsy samples before initiating PPI treatment. This allows differentiation between EoE (high KCNJ2 expression) and PPI-REE (low KCNJ2 expression) upfront, eliminating the need for a time-consuming PPI trial period to observe treatment response.

Inventive Principle:

Principle #10Preliminary action

2Ease of operation

If PPI monotherapy is used for both EoE and PPI-REE, then treatment simplicity is maintained, but EoE patients receive ineffective treatment delaying proper therapy

Engineering Contradiction:

Improvetreatment simplicityVSAvoidtreatment effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent applies local quality by using KCNJ2 expression levels as a specific biomarker to differentiate between EoE and PPI-REE, enabling tailored treatment strategies. EoE patients (high KCNJ2) receive topical corticosteroids and/or dietary elimination, while PPI-REE patients (low KCNJ2) receive PPI monotherapy, optimizing treatment effectiveness for each condition.

Inventive Principle:

Principle #3Local quality

3Device complexity

If no biomarker is used for differentiation, then diagnostic methods remain simple, but the inability to distinguish EoE from PPI-REE leads to unclear therapeutic strategies

Engineering Contradiction:

Improvediagnostic complexityVSAvoidpathogenic information

Core Design Contradiction:

Device complexityVSLoss of information

Solution Approach 1:

The patent introduces KCNJ2 gene or protein expression as an intermediary biomarker that mediates the differentiation between EoE and PPI-REE. This molecular marker provides critical pathogenic information that distinguishes food allergen-driven EoE from acid-responsive PPI-REE, enabling precise therapeutic decision-making without excessive diagnostic complexity.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP3177738B1Diagnostic method for distinguishing forms of esophageal eosinophilia

Publication Date: 2019.10.09 CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI

Figure 1A~1E
Figure 2A~2D
Figure 3A

AI summary

The invention provides methods for diagnosing eosinophilic esophagitis in a patient using a biomarker based assay directed to KCNJ2/Kir2.1 and related compositions, kits, and computer program products.